Limited variation in vaccine candidate Plasmodium falciparum Merozoite Surface Protein-6 over multiple transmission seasons
© Neal et al; licensee BioMed Central Ltd. 2010
Received: 27 January 2010
Accepted: 24 May 2010
Published: 24 May 2010
Plasmodium falciparum Merozoite Surface Protein-6 (PfMSP6) is a component of the complex proteinacious coat that surrounds P. falciparum merozoites. This location, and the presence of anti-PfMSP6 antibodies in P. falciparum-exposed individuals, makes PfMSP6 a potential blood stage vaccine target. However, genetic diversity has proven to be a major hurdle for vaccines targeting other blood stage P. falciparum antigens, and few endemic field studies assessing PfMSP6 gene diversity have been conducted. This study follows PfMSP6 diversity in the Peruvian Amazon from 2003 to 2006 and is the first longitudinal assessment of PfMSP6 sequence dynamics.
Parasite DNA was extracted from 506 distinct P. falciparum infections spanning the transmission seasons from 2003 to 2006 as part of the Malaria Immunology and Genetics in the Amazon (MIGIA) cohort study near Iquitos, Peru. PfMSP6 was amplified from each sample using a nested PCR protocol, genotyped for allele class by agarose gel electrophoresis, and sequenced to detect diversity. Allele frequencies were analysed using JMP v.18.104.22.168 and correlated with clinical and epidemiological data collected as part of the MIGIA project.
Both PfMSP6 allele classes, K1-like and 3D7-like, were detected at the study site, confirming that both are globally distributed. Allele frequencies varied significantly between transmission seasons, with 3D7-class alleles dominating and K1-class alleles nearly disappearing in 2005 and 2006. There was a significant association between allele class and village location (p-value = 0.0008), but no statistically significant association between allele class and age, sex, or symptom status. No intra-allele class sequence diversity was detected.
Both PfMSP6 allele classes are globally distributed, and this study shows that allele frequencies can fluctuate significantly between communities separated by only a few kilometres, and over time in the same community. By contrast, PfMSP6 was highly stable at the sequence level, with no SNPs detected in the 506 samples analysed. This limited diversity supports further investigation of PfMSP6 as a blood stage vaccine candidate, with the clear caveat that any such vaccine must either contain both alleles or generate cross-protective responses that react against both allele classes. Detailed immunoepidemiology studies are needed to establish the viability of these approaches before PfMSP6 advances further down the vaccine development pipeline.
The search for an effective Plasmodium falciparum vaccine has been the focus for research efforts by numerous labs over several decades. While the advancement of the pre-erythrocytic vaccine RTS,S, to Phase III trials raises hopes that a vaccine providing some protection against severe malaria could be on the horizon, clear room for improved efficacy remains even within the context of RTS,S , making P. falciparum vaccine development an ongoing and urgent priority. However, P. falciparum presents an overwhelming number of potential vaccine targets, both because its complex life cycle presents several potential stages to target and because the size of the genome presents multiple potential targets at each stage . Given the finite resources available, it is not feasible for every antigen to advance to vaccine trials; there is, therefore, an urgent need for a more rational approach to candidate selection. Such concerns are highlighted by the collaborative Malaria Vaccine Technology Roadmap , which proposes that all potential candidates progressing through the vaccine development pipeline be subjected to strict go/no-go criteria; similar issues have been discussed in detail in recent reviews [4, 5]. The acquisition of field data describing vaccine candidate sequence diversity and antigenicity in various transmission environments is one key component of these pipeline checkpoints.
Plasmodium falciparum Merozoite Surface Protein-6 (PfMSP6) is a potential vaccine candidate at an early stage in development, which still lacks critical field data to inform the go/no-go decisions necessary to either advance it down the pipeline or remove it from consideration. PfMSP6 is a secreted antigen that is proteolytically processed by PfSUB1 into a 36 kDa fragment that associates with fragments of PfMSP1 and PfMSP7 to form a multi-subunit complex on the merozoite surface [6–8]. PfMSP6 is encoded by one gene in a multi-gene family arranged in close proximity along chromosome 10 . All members of this multi-gene family appear to encode merozoite surface antigens, one of which, PfMSP3, has already advanced to several Phase I vaccine trials [10–12]. Although the function of PfMSP6 remains unknown, it has been postulated to participate in erythrocyte recognition and binding, as have many other merozoite surface proteins of unknown functions. PfMSP6 is, therefore, in the right place to be a theoretical vaccine candidate, and its potential is supported by field studies that have observed anti-PfMSP6 antibody responses in serum from P. falciparum-infected individuals, which inhibit P. falciparum growth in vitro[13, 14]. However, like many potential vaccine antigens, few detailed genetic or immunoepidemiology studies have been carried out in endemic settings.
Recent studies of two of the most advanced blood stage candidates, PfMSP1 and PfAMA1, have made it clear that sequence diversity is a major hurdle for blood stage vaccines , and PfMSP6 is no exception. Past studies of PfMSP6 have shown that like other major merozoite surface antigens PfMSP1 and PfMSP2 , it is dimorphic. The two major PfMSP6 allele classes are referred to as K1- and 3D7-like alleles, named for the strains in which they were first identified . Differences between the alleles are largely restricted to a series of indels in the N-terminal domain, but also include single nucleotide polymorphisms (SNPs) within each allele class that are found in both the N-terminal domain preceding the PfSUB1 cleavage site as well as the generally more conserved C-terminal domain [17, 18]. A recent study of 89 PfMSP6 gene sequences from around the world identified 7 K1-like and 11 3D7-like haplotypes .
Although a series of studies have now given a global picture of PfMSP6 diversity, no study has assessed how extensively PfMSP6 sequences can vary longitudinally at a single study site. To fill this knowledge gap we analysed samples collected between 2003 and 2006 as part of the Malaria Immunology and Genetics in the Amazon (MIGIA) longitudinal cohort study in Zungarococha, a community of four villages located near Iquitos in the Peruvian Amazon. Zungarococha is a hypoendemic transmission environment, with a P. falciparum transmission rate of 0.13 infections/person/month during the seven-month transmission season . Consistent with the hypoendemic transmission, P. falciparum infections seem to routinely consist of few co-infecting genotypes, but genetic diversity is still easily detectable at the population level with at least five haplotypes defined for PfMSP1 Block 2 in this community . The MIGIA project is therefore uniquely suited for vaccine candidate studies, as it allows for the tracking of relatively genetically simple P. falciparum infections that are widely spaced temporally but with considerable genetic diversity at the population level. Furthermore, since samples are collected as part of an ongoing longitudinal study, genotype data can be correlated with detailed clinical and epidemiological data. To further clarify the potential of PfMSP6 as a vaccine candidate, PfMSP6 sequence diversity was characterized in 506 P. falciparum samples collected between 2003 and 2006 as part of the MIGIA cohort, and the resulting genotypes were compared with clinical and epidemiological data. The results inform the rational assessment of PfMSP6 as a vaccine candidate.
A complete description of the MIGIA longitudinal cohort study has been published previously . In brief, the study site consists of four villages that comprise the Zungarococha community: Zungarococha village, Puerto Almendra, Ninarumi, and Llanchama. The community is located in a stable hypoendemic malaria transmission environment. Since 1994, both P. vivax and P. falciparum have been transmitted during the annual seven-month malaria season between January and July, with the primary vector being Anopheles darlingi. Community residents have equal access to healthcare in the community health centre staffed by MIGIA cohort physicians, live in similar housing conditions, and have similar income levels. Travel outside of the community is rare, as women typically work in or near their home and men work in local agriculture or as fishermen along the nearby Nanay River, a tributary of the Amazon River. Travel that does occur is frequently to Iquitos, a city free of malaria transmission.
Blood collection and DNA extraction
The sample collection process, involving both passive and active case detection, has been detailed previously . Briefly, passive case detection occurs when symptomatic individuals seek care at the community health outpost, where confirmation of malaria is made by microscopy. In contrast, active case detection occurs through routine community visits and identifies asymptomatic individuals. This study design increases the likelihood of sampling both symptomatic and asymptomatic P. falciparum infections. All patients submit a 0.5 ml blood sample and, upon malaria diagnosis are re-evaluated, submit another blood sample, and are cleared of parasites by co-administration of mefloquine and artesunate. Samples are separated by centrifugation into serum and packed erythrocyte fractions. Plasmodium DNA is extracted from the erythrocyte fraction using a Blood DNA kit (Qiagen), and the species is identified by PCR using species-specific primers. All samples are catalogued and stored at -80°C until needed. For this study, P. falciparum isolates collected between from 2003 to 2006 were selected at random, excluding only subsequent infections in the same individual that occurred within 60 days of the initial infection in order to reduce the risk of duplication due to parasite recrudescence.
Nested PCR and genotyping
The region of PfMSP6 where all detected inter- and intra-allele genetic diversity has been shown to occur was amplified using a nested PCR protocol with the external primers 5'--CGTGAATACTATTTTCGTTACTT--3' and 5'--CAGCAGTCTTTTTTGTTTCAT--3' and the internal primers 5'--CCCCATCAATCTTATGTCCAG--3' and 5'--CACTTTCTTCATCTATGTCATCTTCTT--3'. The amplified fragment corresponds to nucleotides 221-784 of the reference 3D7 PfMSP6 sequence, excluding primer sequences. 1.0 μl of genomic DNA, extracted from P. falciparum-infected patients, was amplified using ChoiceTaq (Denville) in 35 cycles of 95°C for 30 seconds, 51.1°C for 30 seconds, 65°C for 1 minute, and 65°C for 5 minutes. For the nested PCR reaction, all conditions remained the same except that 1 μl of the primary PCR reaction was used as the template. Multiple negative controls were included in each PCR experiment to monitor for contamination. Allele-typing of PfMSP6 was performed using ethidium bromide-stained agarose gel electrophoresis. PfMSP6 amplified from the P. falciparum strains HB3 and Dd2 were used as controls and run on all agarose gels to aid classification of infections as either 3D7-like or K1-like allele type. All PCR products were subsequently sequenced using sequencing primer 5'--CTTCTTCATTTTCTTCTATCTC--3'. Sequence alignment was performed using CodonCode Aligner 3.0.3 (CodonCode Corporation).
Descriptive statistics, such as allele frequencies, percentages, and means, were used to quantitatively summarize all data sets. Comparisons between allele classes for age group, sex, communities, symptom status, subsequent allele, subsequent P. falciparum infections, year of infection, time to next P. falciparum infection, and comparisons between all other variables of interest were performed using Pearson chi-square or Fisher's exact chi-square, when necessary. Infections were classified as symptomatic if patients experienced febrile illness at least two days prior to diagnosis, had a detected fever ≥ 38.3°C, and/or had a packed cell haematocrit < 30%. Comparisons between means of actual age and days to next P. falciparum infection were performed using the independent t-test. All statistical tests were two-tailed and performed using a 5% significance level in JMP (version 22.214.171.124; SAS Institute, Inc., Cary, NC).
This study was approved by the Institutional Review Boards of the University of Alabama at Birmingham, New York University and the Peruvian Ministerio de Salud, Instituto Naccional de Salud. All participants in the study gave informed consent in writing prior to enrollment in the study.
Significant variation in PfMSP6 allele frequency is observed across transmission seasons
506 samples were selected from P. falciparum infections detected in the MIGIA cohort over the 2003-2006 transmission seasons. Infections that occurred in a given individual within 60 days of a prior infection were excluded. This, combined with the fact that all patients were treated upon detection of a P. falciparum infection (see Methods), significantly reduces the likelihood that any given infection was represented more than once in the sample set.
Correlation of PfMSP6 allele frequencies with epidemiological and clinical data
Association of PfMSP6 allele type with MIGIA cohort study epidemiological data.
< 15 years
≥ 15 years
Association of PfMSP6 allele type with village of residence.
Association of PfMSP6 allele with subsequent infection data.
Subsequent Pf Infection
Next Infection (days)
Sequence variation in PfMSP6 is limited
To investigate intra-allele sequence diversity, all 506 samples were sequenced and compared to published sequences. Any samples that showed potential SNPs were re-amplified and re-sequenced to eliminate the possibility of PCR-induced error. All 3D7-class PfMSP6 alleles were identical to the HB3 strain [GenBank:AY518889], and all K1-class alleles were identical to the K1 strain [GenBank:AY518890]; there was no sequence level diversity across all four transmission seasons.
This sequence stability is in contrast to the adjacent gene on chromosome 10, PfMSP3, which also encodes a related merozoite surface antigen that is under active development as a vaccine candidate [10–12]. Although PfMSP3 sequence diversity at this study site was also limited, previous studies at the same site did reveal rare PfMSP3 sequence variation, all of which shared the same single SNP . Of the 506 samples genotyped for PfMSP6 in this study, 10 had previously been shown to have PfMSP3 SNPs; none of these 10 samples contained PfMSP6 sequence variants.
Comparison of PfMSP3 and PfMSP6 gentoypes revealed some evidence of recombination between these two adjacent genes. PfMSP3 also consists of two defined allele classes, 3D7-like and K1-like [23, 24]. The majority of samples genotyped in both studies contained either both 3D7-class PfMSP3 and 3D7-class PfMSP6 alleles, or K1-class PfMSP3 and K1-class PfMSP6 alleles. Only five samples had mixed PfMSP3 and PfMSP6 alleles, in keeping with established low P. falciparum recombination rates in South America : three infections where a K1-class PfMSP6 allele was paired with a 3D7-class PfMSP3 allele, and two infections where a 3D7-class PfMSP6 allele was paired with a K1-class PfMSP3 allele.
Recent discussions of global malaria elimination as a stated goal for the research community have increased the focus on the decades-long hunt for an effective P. falciparum vaccine . While it is sometimes debated whether a vaccine is a necessary constituent of such campaigns, or precisely which stage should be targeted , the possible emergence of P. falciparum strains resistant to artemisinin, the current front-line drug in global malaria treatment campaigns , emphasizes that it may be premature to reject any approach if the global effort against malaria is to be successful.
While a vaccine targeting a sporozoite stage antigen is currently undergoing Phase III trials , vaccines targeting asexual stage antigens, which in theory would have the clinical advantage of limiting symptoms even if they were not completely effective in eliminating parasites, have lagged somewhat in development. Genetic diversity is clearly a major hurdle for many asexual antigen vaccines , and is presumably responsible for the disappointing results from recent field trials of a PfMSP1-based vaccine . To avoid similar disappointment in the future, it is essential that all potential vaccine candidates undergo rigorous go/no-go analysis in the pre-clinical phase, with candidates being eliminated from consideration if they do not meet certain criteria. Several approaches can be used to inform these go/no-go decisions, including experimental genetic manipulation and detailed field studies investigating both natural genetic diversity and immunoepidemiology.
PfMSP6 is a merozoite candidate antigen at an early stage of pre-clinical development, lacking significant field data that supports its potential role as a viable vaccine candidate. To help inform go/no-go decisions for PfMSP6-based vaccine development, PfMSP6 diversity was followed over multiple transmission seasons in a hypoendemic transmission environment in Peru. At a sequence level, PfMSP6 diversity was very limited in this setting. No intra-allele sequence variants were found in over 500 distinct P. falciparum infections spanning four transmission seasons at the MIGIA cohort study site near Iquitos, Peru. While P. falciparum genetic diversity is, in general, much lower in South America than other regions , SNPs were detected in two other vaccine antigens, PfMSP1 19 and PfMSP3, at the same site over the same period [20, 22]. Genetic stability in low transmission is a generally low bar for vaccine candidate antigens, but the relative stability of the PfMSP6 gene compared to other vaccine antigens even in this setting certainly supports its further investigation as a vaccine candidate.
However, although PfMSP6 was stable at a sequence level, the frequency of the two PfMSP6 allele classes fluctuated significantly between transmission seasons and between villages within the study site. K1 allele-class infections, which are in the minority at this study site just as they appear to be globally , exhibited an overall downward trend over the study period, from 13.2% of total infections in 2003 to 1.0% of total infections in 2006, with a statistically significant drop-off in infections between 2003/2004 and 2005/2006. Within the Zungarococha community, K1-class infections were over-represented in Puerto Almendra (p = 0.0061) and under-represented in Llanchama (p = 0.0007), despite the fact that the two villages are less than 3 km apart. Population differences between the two villages provide a potential explanation. Puerto Almendra is a heavy-traffic village on the Nanay River, and the associated activities of non-residents and position on the riverbank may increase the likelihood of introduction of new allele types through infectious travellers or transport of infected mosquitoes from upstream transmission. Llanchama, by contrast, is the smallest and most isolated village in the community, with little exposure to outside infections.
In addition to measuring PfMSP6 allele-class diversity at the community level, clinical and epidemiological data collected as part of the MIGIA cohort study allowed for the assessment of specific PfMSP6 allele classes with clinical data, which revealed no association of allele class with any clinical data or with any other epidemiological data. The extensive longitudinal data collected as part of the MIGIA study also allowed testing for evidence of allele-specific immunity by assessing whether either infecting allele-class correlated with an increased frequency of subsequent infections, the length of time until subsequent infection, the allele-class of subsequent infections, or an increased frequency of asymptomatic subsequent infections. No significant associations were observed, but the possibility of allele-specific host immune responses should not be excluded due to the lack of statistical power from the infrequent number of infections characteristic of a hypoendemic environment, and the low incidence of K1-class infections in particular.
While the absence of intra-allele class sequence variation in PfMSP6 is a positive attribute for any vaccine candidate, the dynamism of PfMSP6 allele frequencies even in a hypoendemic transmission environment such as the one in the MIGIA cohort emphasizes the fact that any PfMSP6-based vaccine must be able to provide protection against both allele classes. This could be achieved by using a fragment that is conserved between both alleles, or a fragment that is not conserved but is able to induce cross-protection, or by mixing antigens from both allele classes. The simplest way to distinguish between the viability of these approaches it to use immunoepidemiology studies to establish which domains of PfMSP6 are immunogenic in natural P. falciparum infections, and whether the antibodies raised against them are able to cross-react between allele classes.
PfMSP6 is a P. falciparum asexual vaccine candidate with limited pre-clinical data to support its advancement or elimination from further development. Data from P. falciparum infections in the Peruvian Amazon establishes that it is significantly less genetically variable than other merozoite surface vaccine candidate antigens at this site, but PfMSP6 allele frequencies can vary significantly both over time and between local villages. The design of any future PfMSP6-based vaccine must take this data into account and provide protection against both allele classes if it is to warrant further development.
The authors wish to thank Dr. Michael Crowley for his persistence, good humour, and expertise in assisting with SNP detection in PfMSP6, and Patrick Sutton for help with sample processing and obtaining the corresponding epidemiological data. We would like to thank all residents in the Zungarococha community who participate so willingly in the MIGIA cohort study. We thank all the staff of the MIGIA project for sample collection, clinic visits and management, and laboratory sample processing and care. The MIGIA project is a strong collaboration with the Universidad Nacional Amazonia Peruana. This work was supported by the National Institute of Health grants R21 AI072421 and R01 AI064831, and the UAB Sparkman Center for Global Health.
- Ballou WR: The development of the RTS,S malaria vaccine candidate: challenges and lessons. Parasite Immunol. 2009, 31: 492-500. 10.1111/j.1365-3024.2009.01143.x.View ArticlePubMedGoogle Scholar
- Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT, James K, Eisen JA, Rutherford K, Salzberg SL, Craig A, Kyes S, Chan MS, Nene V, Shallom SJ, Suh B, Peterson J, Angiuoli S, Pertea M, Allen J, Selengut J, Haft D, Mather MW, Vaidya AB, Martin DM, Fairlamb AH, Fraunholz MJ, Roos DS, Ralph SA, McFadden GI, Cummings LM, Subramanian GM, Mungall C, Venter JC, Carucci DJ, Hoffman SL, Newbold C, Davis RW, Fraser CM, Barrell B: Genome sequence of the human malaria parasite Plasmodium falciparum. Nature. 2002, 419: 498-511. 10.1038/nature01097.View ArticlePubMedGoogle Scholar
- Malaria Vaccine Technology Roadmap: [http://www.malariavaccineroadmap.net]
- Coppel RL: Vaccinating with the genome: a Sisyphean task?. Trends Parasitol. 2009, 25: 205-212. 10.1016/j.pt.2009.02.006.View ArticlePubMedGoogle Scholar
- Holder AA: Malaria vaccines: where next?. PLoS Pathog. 2009, 5: e1000638-10.1371/journal.ppat.1000638.PubMed CentralView ArticlePubMedGoogle Scholar
- Kauth CW, Woehlbier U, Kern M, Mekonnen Z, Lutz R, Mucke N, Langowski J, Bujard H: Interactions between merozoite surface proteins 1, 6, and 7 of the malaria parasite Plasmodium falciparum. J Biol Chem. 2006, 281: 31517-31527. 10.1074/jbc.M604641200.View ArticlePubMedGoogle Scholar
- Trucco C, Fernandez-Reyes D, Howell S, Stafford WH, Scott-Finnigan TJ, Grainger M, Ogun SA, Taylor WR, Holder AA: The merozoite surface protein 6 gene codes for a 36 kDa protein associated with the Plasmodium falciparum merozoite surface protein-1 complex. Mol Biochem Parasitol. 2001, 112: 91-101. 10.1016/S0166-6851(00)00350-9.View ArticlePubMedGoogle Scholar
- Koussis K, Withers-Martinez C, Yeoh S, Child M, Hackett F, Knuepfer E, Juliano L, Woehlbier U, Bujard H, Blackman MJ: A multifunctional serine protease primes the malaria parasite for red blood cell invasion. EMBO J. 2009, 28: 725-735. 10.1038/emboj.2009.22.PubMed CentralView ArticlePubMedGoogle Scholar
- Singh S, Soe S, Weisman S, Barnwell JW, Perignon JL, Druilhe P: A conserved multi-gene family induces cross-reactive antibodies effective in defense against Plasmodium falciparum. PloS One. 2009, 4: e5410-10.1371/journal.pone.0005410.PubMed CentralView ArticlePubMedGoogle Scholar
- Druilhe P, Spertini F, Soesoe D, Corradin G, Mejia P, Singh S, Audran R, Bouzidi A, Oeuvray C, Roussilhon C: A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med. 2005, 2: e344-10.1371/journal.pmed.0020344.PubMed CentralView ArticlePubMedGoogle Scholar
- Lusingu JP, Gesase S, Msham S, Francis F, Lemnge M, Seth M, Sembuche S, Rutta A, Minja D, Segeja MD, Bosomprah S, Cousens S, Noor R, Chilengi R, Druilhe P: Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months. Malar J. 2009, 8: 163-10.1186/1475-2875-8-163.PubMed CentralView ArticlePubMedGoogle Scholar
- Sirima SB, Tiono AB, Ouedraogo A, Diarra A, Ouedraogo AL, Yaro JB, Ouedraogo E, Gansane A, Bougouma EC, Konate AT, Kabore Y, Traore A, Roma C, Soulama I, Luty AJ, Cousens S, Nebie I: Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children. PloS One. 2009, 4: e7549-10.1371/journal.pone.0007549.PubMed CentralView ArticlePubMedGoogle Scholar
- Singh S, Soe S, Roussilhon C, Corradin G, Druilhe P: Plasmodium falciparum merozoite surface protein 6 displays multiple targets for naturally occurring antibodies that mediate monocyte-dependent parasite killing. Infect Immun. 2005, 73: 1235-1238. 10.1128/IAI.73.2.1235-1238.2005.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang L, Crouch L, Richie TL, Nhan DH, Coppel RL: Naturally acquired antibody responses to the components of the Plasmodium falciparum merozoite surface protein 1 complex. Parasite Immunol. 2003, 25: 403-412. 10.1111/j.1365-3024.2003.00647.x.View ArticlePubMedGoogle Scholar
- Takala SL, Plowe CV: Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'. Parasite Immunol. 2009, 31: 560-573. 10.1111/j.1365-3024.2009.01138.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Roy SW, Ferreira MU, Hartl DL: Evolution of allelic dimorphism in malarial surface antigens. Heredity. 2008, 100: 103-110. 10.1038/sj.hdy.6800887.View ArticlePubMedGoogle Scholar
- Pearce JA, Triglia T, Hodder AN, Jackson DC, Cowman AF, Anders RF: Plasmodium falciparum merozoite surface protein 6 is a dimorphic antigen. Infection Immun. 2004, 72: 2321-2328. 10.1128/IAI.72.4.2321-2328.2004.View ArticleGoogle Scholar
- Roy SW, Weedall GD, da Silva RL, Polley SD, Ferreira MU: Sequence diversity and evolutionary dynamics of the dimorphic antigen merozoite surface protein-6 and other Msp genes of Plasmodium falciparum. Gene. 2009, 443: 12-21. 10.1016/j.gene.2009.05.007.View ArticlePubMedGoogle Scholar
- Branch O, Casapia WM, Gamboa DV, Hernandez JN, Alava FF, Roncal N, Alvarez E, Perez EJ, Gotuzzo E: Clustered local transmission and asymptomatic Plasmodium falciparum and Plasmodium vivax malaria infections in a recently emerged, hypoendemic Peruvian Amazon community. Malaria J. 2005, 4: 27-10.1186/1475-2875-4-27.View ArticleGoogle Scholar
- Sutton PL, Neyra V, Hernandez JN, Branch OH: Plasmodium falciparum and Plasmodium vivax infections in the Peruvian Amazon: propagation of complex, multiple allele-type infections without super-infection. Am J Trop Med Hyg. 2009, 81: 950-960. 10.4269/ajtmh.2009.09-0132.PubMed CentralView ArticlePubMedGoogle Scholar
- Pinedo-Cancino V, Sheen P, Tarazona-Santos E, Oswald WE, Jeri C, Vittor AY, Patz JA, Gilman RH: Limited diversity of Anopheles darlingi in the Peruvian Amazon region of Iquitos. Am J Trop Med Hyg. 2006, 75: 238-245.PubMed CentralPubMedGoogle Scholar
- Jordan SJ, Branch OH, Castro JC, Oster RA, Rayner JC: Genetic diversity of the malaria vaccine candidate Plasmodium falciparum merozoite surface protein-3 in a hypoendemic transmission environment. Am J Trop Med Hyg. 2009, 80: 479-486.PubMed CentralPubMedGoogle Scholar
- Huber W, Felger I, Matile H, Lipps HJ, Steiger S, Beck HP: Limited sequence polymorphism in the Plasmodium falciparum merozoite surface protein 3. Mol Biochem Parasitol. 1997, 87: 231-234. 10.1016/S0166-6851(97)00067-4.View ArticlePubMedGoogle Scholar
- McColl DJ, Silva A, Foley M, Kun JF, Favaloro JM, Thompson JK, Marshall VM, Coppel RL, Kemp DJ, Anders RF: Molecular variation in a novel polymorphic antigen associated with Plasmodium falciparum merozoites. Mol Biochem Parasitol. 1994, 68: 53-67. 10.1016/0166-6851(94)00149-9.View ArticlePubMedGoogle Scholar
- Mu J, Awadalla P, Duan J, McGee KM, Joy DA, McVean GA, Su XZ: Recombination hotspots and population structure in Plasmodium falciparum. PLoS Biol. 2005, 3: e335-10.1371/journal.pbio.0030335.PubMed CentralView ArticlePubMedGoogle Scholar
- Greenwood B: Can malaria be eliminated?. Trans R Soc Trop Med Hyg. 2009, 103 (Suppl 1): S2-5. 10.1016/j.trstmh.2008.10.027.View ArticlePubMedGoogle Scholar
- Greenwood B, Targett G: Do we still need a malaria vaccine?. Parasite Immunol. 2009, 31: 582-586. 10.1111/j.1365-3024.2009.01140.x.View ArticlePubMedGoogle Scholar
- Muller O, Sie A, Meissner P, Schirmer RH, Kouyate B: Artemisinin resistance on the Thai-Cambodian border. Lancet. 2009, 374: 1419-10.1016/S0140-6736(09)61857-2.View ArticlePubMedGoogle Scholar
- Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, Dubovsky F, Tucker K, Waitumbi JN, Diggs C, Wittes J, Malkin E, Leach A, Soisson LA, Milman JB, Otieno L, Holland CA, Polhemus M, Remich SA, Ockenhouse CF, Cohen J, Ballou WR, Martin SK, Angov E, Stewart VA, Lyon JA, Heppner DG, Withers MR: Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PloS One. 2009, 4: e4708-10.1371/journal.pone.0004708.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.